Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA

References

• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Boonen S, Vanderschueren D, Venken K, et al. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 2008;264:315-32
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Babbitt AM, Piziak VK, et al. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 2008;30:605-21
   PubMed Web of Science ®Google Scholar
• Silverman SL, Gold DT. Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 2008;10:118-22
   PubMedGoogle Scholar
• Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16(Suppl 2):S3-7
   PubMed Web of Science ®Google Scholar
• Caliri A, De Filippis L, Bagnato GL, et al. Osteoporotic fractures: mortality and quality of life. Panminerva Med 2007;49:21-7
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004;15:38-42
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
   PubMed Web of Science ®Google Scholar
• Iacovino JR. Mortality outcomes after osteoporotic fractures in men and women. J Insur Med 2001;33:316-20
   PubMedGoogle Scholar
• Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75
   PubMed Web of Science ®Google Scholar
• Keen RW. Burden of osteoporosis and fractures. Curr Osteoporos Rep 2003;1:66-70
   PubMedGoogle Scholar
• Johnell O, Kanis JA, Jonsson B, et al. The burden of hospitalised fractures in Sweden. Osteoporos Int 2005;16:222-8
   PubMed Web of Science ®Google Scholar
• Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year findings from the DIVA study. Arthritis Rheum 2006;54:1838-46
   PubMed Web of Science ®Google Scholar
• Eisman J, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 2008;35:488-97
   PubMed Web of Science ®Google Scholar
• Papapoulos S. Changes in bone remodeling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis 2007;66:853-8
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporosis Int 2008;20:291-7
   PubMed Web of Science ®Google Scholar
• Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-65
   PubMed Web of Science ®Google Scholar
• Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005;44:551-70
   PubMed Web of Science ®Google Scholar
• Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-22
   PubMed Web of Science ®Google Scholar
• Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61
   PubMed Web of Science ®Google Scholar
• Schneider DL, Bettencourt R, Barrett-Connor E. Clinical utility of spine bone density in elderly women. J Clin Densitom 2006;9:255-60
   PubMed Web of Science ®Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
   PubMed Web of Science ®Google Scholar
• Durosier C, Hans D, Krieg MA, et al. Prediction and discrimination of osteoporotic hip fracture in postmenopausal women. J Clin Densitom 2006;9:475-95
   PubMed Web of Science ®Google Scholar
• Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005;20:1185-94
   PubMed Web of Science ®Google Scholar
• Kanis JA, Odén A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003;32:468-73
   PubMed Web of Science ®Google Scholar
• Sernbo I, Johnell O. Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int 1993;3:148-53
   PubMed Web of Science ®Google Scholar
• Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-45
   PubMed Web of Science ®Google Scholar
• Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 2008;75:303-10
   PubMed Web of Science ®Google Scholar
• Cooper A, Drake J, Brankin E; the PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905
   Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva ALendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903
   PubMed Web of Science ®Google Scholar